Welcome to our dedicated page for Option Care Health news (Ticker: OPCH), a resource for investors and traders seeking the latest updates and insights on Option Care Health stock.
News about Option Care Health, Inc. (OPCH) centers on its role as the nation’s largest independent provider of home and alternate site infusion services and on its regular financial and corporate updates. The company issues detailed quarterly earnings releases, often accompanied by Form 8-K filings, that cover net revenue, net income, earnings per share, and non-GAAP metrics such as Adjusted EBITDA, Adjusted net income and Adjusted diluted EPS.
Investors following OPCH news will see announcements of preliminary and final quarterly and full-year financial results, as well as updated financial guidance ranges for net revenue, Adjusted EBITDA and Adjusted diluted earnings per share. These releases typically include management commentary on performance, cash flow from operations, stock repurchase activity and capital structure developments.
Option Care Health also uses news releases to communicate capital allocation decisions, such as expansions of its share repurchase program authorization, and to describe amendments to its credit agreements that affect term loans and revolving credit facilities. SEC Form 8-K filings referenced in the news provide additional detail on these material definitive agreements and financial obligations.
Corporate governance and leadership changes are another recurring news theme. For example, the company has announced a Chief Financial Officer transition, outlining the incoming CFO’s background, compensation arrangements and the outgoing CFO’s advisory role. News items also highlight Option Care Health’s participation in major healthcare and finance conferences, including events hosted by J.P. Morgan, UBS, Jefferies, Deutsche Bank and Bank of America, with webcasts and presentation materials made available to investors.
In addition, Option Care Health appears in partner company releases, such as Quince Therapeutics’ announcements of a strategic relationship for specialty infusion therapy support. These items describe how Option Care Health’s national network of specialty pharmacies and ambulatory infusion suites may be used to administer specific infused therapies, particularly in rare disease indications. For ongoing coverage of these financial, strategic and operational developments, OPCH news on this page aggregates company press releases, partner announcements and related disclosures.
Option Care Health (Nasdaq: OPCH) reported preliminary unaudited results for Q4 and full year 2025 and provided preliminary guidance for full year 2026. Q4 2025 net revenue is expected to be $1.46–1.47B, GAAP diluted EPS $0.37–0.39, adjusted diluted EPS $0.46–0.49, and adjusted EBITDA $123.7–127.7M. Full year 2025 net revenue is expected at $5.645–5.655B, GAAP diluted EPS $1.27–1.29, adjusted diluted EPS $1.72–1.76, adjusted EBITDA $469–473M, and operating cash flow below $320M. 2026 guidance calls for net revenue $5.8–6.0B, adjusted diluted EPS $1.82–1.92, and adjusted EBITDA $480–505M. The board expanded the share repurchase authorization to $1.0B (added $500M); ~$307M was repurchased in 2025.
Option Care Health (Nasdaq: OPCH) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 with a presentation at 10:30am PT.
The company said the webcast and presentation materials will be available at https://investors.optioncarehealth.com. Option Care Health describes itself as the nation’s largest independent provider of home and alternate site infusion services, with over 8,000 team members including more than 5,000 clinicians serving all 50 states.
Option Care Health (Nasdaq: OPCH) will participate in four investor conferences in November–December 2025, presenting corporate updates and fielding investor questions.
Schedule: UBS Global Healthcare in Palm Beach on Nov 11, 2025 at 3:30pm ET; Jefferies London Healthcare in London on Nov 19, 2025 at 3:30pm GMT; Bank of America Leveraged Finance in Boca Raton on Dec 2, 2025 at 10:50am ET; and Bank of America Home Care (virtual) on Dec 8, 2025 at 10:50am ET.
Webcasts and presentation materials, if applicable, will be available at https://investors.optioncarehealth.com. The company states it employs over 8,000 team members including more than 5,000 clinicians and provides home and alternate site infusion services across all 50 states.
Option Care Health (Nasdaq: OPCH) reported third-quarter 2025 results for the period ended September 30, 2025: net revenue $1.435B (+12.2% YoY), gross profit $272.9M (+6.3% YoY), net income $51.8M (-3.8% YoY) and GAAP diluted EPS $0.32. Adjusted metrics: Adjusted EBITDA $119.5M (+3.4% YoY) and Adjusted diluted EPS $0.45 (+9.8% YoY). The company repurchased $62.5M of stock in the quarter, expanded a term loan by $49.6M with a lower rate, and reported YTD operating cash flow of $222.6M.
Updated 2025 guidance: revenue $5.60–5.65B, Adjusted EPS $1.68–1.72, Adjusted EBITDA $468–473M, and cash flow from operations ≥ $320M.
Option Care Health (NASDAQ: OPCH), the largest independent provider of home and alternate site infusion services in the US, has scheduled its Q3 2025 earnings release for Thursday, October 30, 2025, before market opens.
The company will host a conference call at 8:30 a.m. ET on the same day to discuss the results. Investors can pre-register for the call or access it via webcast at investors.optioncarehealth.com. A replay will be available for approximately 90 days after the call.
Option Care Health (NASDAQ:OPCH), the largest independent provider of home and alternate site infusion services in the US, announced its participation in two upcoming investor conferences. The company will attend the Deutsche Bank Healthcare Summit in New York City (September 10-11, 2025) and the Jefferies Healthcare Services Conference in Nashville (September 30, 2025), where they will participate in a fireside chat at 2:15pm ET.
Option Care Health operates nationwide with over 8,000 team members, including more than 5,000 clinicians, providing infusion services for patients with acute and chronic conditions across all 50 states.
Option Care Health (Nasdaq: OPCH), the largest independent provider of home and alternate site infusion services in the US, announced a significant leadership transition. Meenal Sethna will join as Executive Vice President and CFO effective October 1, 2025, succeeding Mike Shapiro, who will step down after 10 years with the company.
Sethna brings over 30 years of experience and most recently served as EVP and CFO at Littelfuse, Inc. Shapiro will remain as Strategic Advisor through Q1 2026 to ensure a smooth transition. The change comes as Option Care Health maintains strong momentum in its mission to deliver extraordinary care and create long-term shareholder value.
Quince Therapeutics (Nasdaq: QNCX) announced significant progress in Q2 2025, highlighted by the completion of enrollment in its pivotal Phase 3 NEAT clinical trial for A-T treatment. The trial enrolled 105 participants, with topline results expected in Q1 2026. The company secured financing that brought its cash position to $34.7 million, providing runway through Phase 3 results into Q2 2026.
Key financial results include R&D expenses of $6.6 million, G&A expenses of $3.3 million, and a net loss of $16.1 million ($0.34 per share). Quince entered a strategic partnership with Option Care Health for U.S. commercial launch support and closed a premium-priced private placement led by Nantahala Capital, generating $11.5 million in upfront proceeds with potential additional proceeds of up to $10.4 million from warrants.
Quince Therapeutics (Nasdaq: QNCX) has established a strategic partnership with Option Care Health (Nasdaq: OPCH) for the commercial development and launch of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP) in the United States.
Option Care Health will provide nationwide specialty pharmacy and infusion services through its network of 90+ pharmacies and 180+ ambulatory infusion suites. The partnership aims to enhance access to eDSP treatment for patients with Ataxia-Telangiectasia (A-T), with potential expansion to treat Duchenne muscular dystrophy (DMD).
The collaboration includes comprehensive services such as logistics management, patient registration, hub support, clinician-delivered services, and data reporting to support eDSP's commercial launch, pending positive study results and regulatory approval.
Option Care Health (Nasdaq: OPCH), the largest independent provider of home and alternate site infusion services, reported strong Q2 2025 financial results. The company achieved net revenue of $1.42 billion, up 15.4% year-over-year, with net income of $50.5 million.
Key financial metrics include gross profit of $269.0 million (19.0% of revenue), Adjusted EBITDA of $114.0 million (up 5.2%), and diluted EPS of $0.31. The company repurchased approximately $50.0 million of stock during Q2.
Option Care Health updated its FY2025 guidance, projecting revenue of $5.50-5.65 billion, adjusted EPS of $1.65-1.72, and adjusted EBITDA of $465-475 million. The company expects cash flow from operations of at least $320 million.
FAQ
What is the current stock price of Option Care Health (OPCH)?
What is the market cap of Option Care Health (OPCH)?
